Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Beijing Friendship Hospital: Clinical Trials & FDA Approval Profile

Beijing Friendship Hospital (Global / Institutional) sponsors 34 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 11 active protocols (8 recruiting now), 3 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)29 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Beijing Friendship Hospital
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)34
Active Pipeline (Recruiting Now)11 (8)
Completed vs Stopped Early3 / 0 (0.0%)
Median Closed Actual Enrollment29 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Beijing Friendship Hospital
Hospital Research SiteLocationShared Protocols
Beijing Friendship Hospital , Capital Medical UniversityBeijing19
Peking Union Medical College HospitalBeijing, Beijing Municipality2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Beijing Friendship Hospital
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05245474Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal CancerPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Beijing Friendship Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI